Treatment of a compound heterozygous familial hypercholesterolemia patient with lomitapide
Atherosclerosis(2014)
Abstract
Objectives: The aim of this study is to evaluate the effects of Lomitapide, the first MTP-inhibitor recently approved by FDA and EMA for treatment of homozygous and compound heterozygous familial hypercholesterolemia (FH) patients. These patients present with severely increased LDL-cholesterol levels due to absence/dysfunction of LDL-receptors and consequently, with an extremely increased risk of cardiovascular disease (CVD) and early death. Conventional treatments are not sufficient in reducing the risk of CVD.
MoreTranslated text
Key words
Cholesterol-lowering
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined